Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Forzinity Barth Syndrome Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C30298-A

    Forzinity (elamipretide) for Barth syndrome

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C30298-A alerts

    Get alerted when Policy C30298-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage for Forzinity (elamipretide), a once-daily subcutaneous treatment for patients with genetically confirmed Barth syndrome. It establishes initial and continuation criteria, prescriber and administration requirements, exclusions, and documentation needed for coverage.

    Policy Summary
    PayerMolina Healthcare
    PolicyForzinity (elamipretide) for Barth syndrome
    Policy CodePolicy C30298-A
    Change TypeNew criteria creationcontinuation requirements revised
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionObtain prior authorization and submit documentation of Barth syndrome, TAZ gene confirmation, baseline disease activity and treatment goals, and member weight of at least 30 kg.
    SourceLink
    POLICY UPDATE CHANGES

    The policy establishes new coverage criteria for Forzinity (elamipretide) for Barth syndrome.

    Continuation-of-therapy requirements and the expanded access appendix were revised.

    12+Minimum age for coverage
    30 kgMinimum member weight
    40 mg/dayCovered dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Authorization duration
    SubcutaneousRoute of administration
    ExcludedOther uses

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when ALL of the following are met:

    • Diagnosis and genetic confirmation

      • The member has a documented diagnosis of Barth syndrome.
      • Genetic testing confirms mutations in the TAZ gene.
    • Baseline evaluation and treatment goals: The prescriber documents a baseline disease activity evaluation and treatment goals to evaluate efficacy at renewal, such as a 6-minute walk test or other functional test, fatigue assessment, activities of daily living assessment, muscle strength assessment, or cardiac evaluation.

      The same assessment should be used for reauthorization. If the initial assessment tool is no longer appropriate because of a change in member status or age range, submit the rationale for changing the tool.

    • Weight requirement: The member weighs at least 30 kg.>= 30 kg
    • Age requirement: The member is 12 years of age or older.>= 12 years

    Continuation Therapy

    Covered for continuation therapy when ALL of the following are met:

    • Tolerability: The prescriber attests, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.
    • Clinical response: Documentation demonstrates a positive or stable clinical response, shown by low disease activity and/or improvement in the condition's signs and symptoms, such as on a 6-minute walk test or other functional test, fatigue assessment, activities of daily living assessment, muscle strength assessment, or cardiac evaluation.

      Use the same assessment provided at initial review. If the initial assessment tool is no longer appropriate because of a change in member status or age range, submit the rationale for changing the tool.

    Do not use Forzinity in patients with serious hypersensitivity to any of its ingredients or in neonates.

    Forzinity has not been studied in patients undergoing a pubertal growth spurt, patients with uncontrolled hypertension, patients with a history of heart transplant or who are awaiting heart transplant, or patients with an implantable cardioverter-defibrillator with recent discharge or expected ICD placement.

    There is insufficient information to recommend a dosage regimen for adults with eGFR less than 30 mL/minute who are on dialysis or for pediatric patients weighing 30 kg or greater with renal impairment.

    All other uses of Forzinity (elamipretide) outside the covered Barth syndrome indication are considered experimental or investigational and are not covered under this policy.

    Coverage Parameters

    Minimum Member Weight
    Minimum eligible weightAt least 30 kg
    Coverage applicationRequired for initial therapy eligibility
    Policy wordingDocumentation that the member weighs at least 30 kg is required
    Minimum Age
    Minimum eligible age12 years of age and older
    Coverage applicationRequired for initial therapy eligibility
    Policy wordingMembers must be 12 years of age or older

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Submit a prior authorization request documenting that the member meets the initial Barth syndrome coverage criteria for Forzinity (elamipretide). Initial authorization is approved for 12 months when all required clinical, diagnostic, prescriber, age, weight, and assessment documentation is provided.

    • Documented Barth syndrome diagnosis confirmed by genetic testing showing mutations in the TAZ gene.
    • Submit baseline disease activity evaluation and treatment goals, including applicable functional, fatigue, activities-of-daily-living, muscle-strength, or cardiac assessments.
    • Document member age of at least 12 years and weight of at least 30 kg.
    • Medication is prescribed by, or in consultation with, a board-certified cardiologist, neuromuscular disorder specialist, neurologist, endocrinologist, hematologist, or geneticist.
    Prior Authorization

    Continuation Prior Authorization

    For reauthorization, submit documentation supporting continued therapy and the member’s response or tolerability. Continuation authorization is approved for 12 months when the member has no intolerable adverse effects or drug toxicity and demonstrates a positive or stable clinical response.

    Disease and Treatment Background

    Barth syndrome is an ultra-rare, X-linked genetic disorder caused by mutations in the TAZ gene, also known as G4.5 or tafazzin. It primarily affects males and may cause cardiomyopathy, neutropenia, low muscle mass, muscle weakness, growth delay, exercise intolerance, feeding problems, cardiolipin abnormalities, and 3-methylglutaconic aciduria.

    Drug Definitions

    Drug Class
    Drug classMitochondrial cardiolipin binder
    DrugForzinity (elamipretide)
    Therapeutic contextFor the treatment of Barth syndrome
    Accelerated Approval
    Approval basisImprovement in knee extensor muscle strength
    Endpoint typeIntermediate clinical endpoint
    Confirmatory evidenceContinued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s)

    Initial Therapy

    Initial Therapy

    Initial therapy requires ALL criteria below:

    • Diagnosis and genetic confirmation

      • The member has a documented diagnosis of Barth syndrome.
      • Genetic testing confirms mutations in the TAZ gene.
    • Baseline disease activity and treatment goals: The prescriber documents a baseline disease activity evaluation and treatment goals for evaluating efficacy at renewal, using a 6-minute walk test or other functional test, fatigue assessment, activities of daily living assessment, muscle strength assessment, cardiac evaluation, or another appropriate assessment.

      The same assessment should be used at reauthorization. If the initial assessment tool is not appropriate because of a change in member status or age range, submit the rationale for changing the assessment tool.

    Continuation Therapy

    Continuation Therapy

    Continuation therapy requires ALL criteria below:

    • Tolerability: The prescriber attests, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.
    • Positive or stable clinical response: Documentation demonstrates a positive or stable clinical response through low disease activity and/or improvement in the condition's signs and symptoms, using a 6-minute walk test or other functional test, fatigue assessment, activities of daily living assessment, muscle strength assessment, cardiac evaluation, or another appropriate assessment.

      The same assessment used at initial review should be used for continuation. If the initial assessment tool is not appropriate because of a change in member status or age range, submit the rationale for changing the assessment tool.

    Dose and Quantity Limits

    Quantity Limits
    Covered drugForzinity (elamipretide)
    Covered dose40 mg once daily
    Route of administrationSubcutaneous

    Administration and Site of Care

    Billing Rule

    Use pharmacy benefit and self-administration

    Injectable Forzinity is recommended for pharmacy benefit coverage and patient self-administration.

    Policy Summary
    PayerMolina Healthcare
    PolicyForzinity (elamipretide) for Barth syndrome
    Policy CodePolicy C30298-A
    Change TypeNew criteria creationcontinuation requirements revised
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionObtain prior authorization and submit documentation of Barth syndrome, TAZ gene confirmation, baseline disease activity and treatment goals, and member weight of at least 30 kg.
    SourceLink
    On This Page
    Coverage CriteriaCoverage ParametersAuthorization and Documentation RequirementsDisease and Treatment BackgroundDrug DefinitionsInitial TherapyContinuation TherapyDose and Quantity LimitsAdministration and Site of Care
    • Prescriber attestation or clinical reviewer finding of no intolerable adverse effects or drug toxicity.
    • Document positive or stable clinical response, demonstrated by low disease activity and/or improvement in signs and symptoms using the applicable functional, fatigue, activities-of-daily-living, muscle-strength, or cardiac assessment.
    • Use the same assessment provided at initial review unless a change is clinically appropriate and the rationale is submitted.
    • Continuation authorization duration: 12 months.
    Documentation Required

    General Medical Necessity Documentation

    Molina may require complete medical rationale and supporting documentation to determine coverage, medical necessity, and whether the requested treatment is non-investigational and within the member’s benefits. Submit records sufficient to support the request and the credentials of the provider ordering or performing the service.

    • Provide complete medical rationale for the request, including any requested exception.
    • Submit relevant patient records and test results.
    • Submit prescriber or ordering-provider credentials when requested.
    • Insufficient or unsupported documentation may result in denial of reimbursement or other appropriate action.
    Documentation Required

    Diagnosis and Genetic Confirmation

    Document the member’s Barth syndrome diagnosis and confirm the diagnosis through genetic testing demonstrating mutations in the TAZ gene.

    • Diagnosis: Barth syndrome.
    • Genetic confirmation: TAZ gene mutations documented by genetic testing.
    Documentation Required

    Baseline Disease Activity and Treatment Goals

    Before initial authorization, document a baseline disease activity evaluation and the goals for treatment that will be used to assess efficacy at renewal.

    • Use an applicable baseline assessment such as a 6-minute walk test or other functional test, fatigue assessment, activities-of-daily-living assessment, muscle-strength assessment, or cardiac evaluation.
    • Document measurable treatment goals linked to the baseline findings.
    Documentation Required

    Follow-Up Assessment Documentation

    For reauthorization, submit a follow-up assessment using the same assessment tool provided at initial review. If the original tool is no longer appropriate because of a change in the member’s status or age range, submit the rationale for changing the tool.

    • Document follow-up disease activity and clinical response using the initial assessment method whenever appropriate.
    • Explain and support any change in assessment tool.
    Documentation Required

    Specialist Consultation Notes

    When the medication is prescribed in consultation, submit the consultation notes with both the initial authorization request and each reauthorization request.

    • The prescriber must be or consult with a board-certified cardiologist, neuromuscular disorder specialist, neurologist, endocrinologist, hematologist, or geneticist.
    • Consultation notes are required for initial and renewal requests when consultation is used to satisfy the prescriber requirement.
    Denial Risk

    Initial Authorization Criteria Not Met

    Initial authorization may be denied when the required diagnosis, genetic confirmation, baseline disease activity evaluation, treatment goals, or other initial coverage criteria are missing or not met.

    • Barth syndrome is not documented.
    • Genetic testing does not document a TAZ gene mutation.
    • Baseline disease activity evaluation or treatment goals are not submitted.
    • Member does not meet the documented age or weight requirements, or required specialist prescribing or consultation documentation is absent.
    • The submitted records do not establish medical necessity or otherwise support the initial request.
    Denial Risk

    Continuation Response or Tolerability Not Demonstrated

    Continuation authorization may be denied when tolerability or clinical benefit is not demonstrated. The request must support ongoing therapy without intolerable adverse effects or drug toxicity and must document a positive or stable response.

    • Intolerable adverse effects or drug toxicity are present or not adequately addressed.
    • Low disease activity or improvement in signs and symptoms is not demonstrated.
    • Required follow-up assessment documentation is missing, or the assessment differs from the initial tool without a submitted rationale.
    Denial Risk

    Contraindication

    Do not use Forzinity in members with serious hypersensitivity to any of its ingredients or in neonates.

    • Serious hypersensitivity to any ingredient: contraindicated.
    • Neonatal use: do not use.
    Denial Risk

    Non-Covered or Investigational Use

    Coverage is limited to the covered Barth syndrome indication described in this policy. All other uses of Forzinity (elamipretide) are considered experimental or investigational and follow Molina’s Off-Label policy.

    • Non-covered or investigational uses outside the covered Barth syndrome indication are excluded from coverage under this guideline.
    • Requests for other uses are subject to Molina’s Off-Label policy.
    Note

    Renal Impairment Limitation

    There is insufficient information to recommend a dosing regimen for certain patients with renal impairment. Coverage or dosing recommendations are limited for adults with eGFR below 30 mL/minute or on dialysis and for pediatric patients weighing at least 30 kg with renal impairment.

    • Adults with eGFR <30 mL/minute: insufficient dosing information.
    • Adults on dialysis: insufficient dosing information.
    • Pediatric patients weighing at least 30 kg with renal impairment: insufficient dosing information.
    Weight requirement: The member weighs at least 30 kg.>= 30 kg
  1. Age requirement: The member is 12 years of age or older.>= 12 years